EDITORIAL Should addiction researchers be interested in psychedelic science ? Stephen Bright, Martin Williams & David Caldicott Australasian Professional Society on Alcohol and other Drugs, Drug and Alcohol Review, 2017 DOI: 10.1111/dar.12544 As recently noted by Strauss, Bright and Williams [1], while much of the Western world has been experiencing a renaissance in research into ‘psychedelic science’ over the past decade [2], there has been no such research conducted in Australia. In Europe and the USA, studies have been conducted into lysergic acid diethylamide (LSD) that have improved our understanding of brain function [3] and reduced existential anxiety associated with dying [4], while psilocybin-assisted psychotherapy has [...]
Lire la suiteCannabinol and Neuropathic Pain P.W. Brownjohn and J.C. Ashton Neuropathic Pain, 2012, chap. 4, 79-102 1. Introduction Cannabinoids are drugs that are either derived from cannabis or that induce similar behavioural and physiological effects to cannabis. They fall into three classes: those that are produced by plants of the Cannabis genus, termed phytocannabinoids (plant cannabinoids); those that are produced within the body, termed endocannabinoids (endogenous cannabinoids); and those that are produced synthetically to mimic the pharmacology of naturally occurring cannabinoids. Cannabinoids stand in relation to cannabis as opioids such as codeine, pethidine, fentanyl, and methadone stand in relation to opium. While opium and opioids [...]
Lire la suiteREBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics R. L. Carhart-Harris and K. J. Friston Pharmacological Reviews, 2019, 71, 316–344 https://doi.org/10.1124/pr.118.017160 Significance Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 I. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . [...]
Lire la suiteSpectral signatures of serotonergic psychedelics and glutamatergic dissociatives Carla Pallavicini, Martina G. Vilas, Mirta Villarreal, Federico Zamberlan, Suresh Muthukumaraswamy, David Nutt, Robin Carhart-Harris, Enzo Tagliazucchi NeuroImage, 2019 https://doi.org/10.1016/j.neuroimage.2019.06.053 Abstract Classic serotonergic psychedelics are remarkable for their capacity to induce reversible alterations in consciousness of the self and the surroundings, mediated by agonism at serotonin 5-HT2A receptors. The subjective effects elicited by dissociative drugs acting as N-methyl-D-aspartate (NMDA) antagonists (e.g. ketamine and phencyclidine) overlap in certain domains with those of serotonergic psychedelics, suggesting some potential similarities in the brain activity patterns induced by both classes of drugs, despite different pharmacological mechanisms of action. We investigated source-localized [...]
Lire la suitePrevalence and epidemiological associates of novel psychedelic use in the United States adult population James D. Sexton, Michael S. Crawford, Noah W. Sweat, Allyson Varley , Emma E. Green and Peter S. Hendricks Journal of Psychopharmacology, 1-10 DOI : 10.1177/0269881119827796 journals.sagepub.com/home/jopract Abstract Background : Novel psychedelics approximate classic psychedelics, but unlike classic psychedelics, novel psychedelics have been used by humans for a shorter period of time, with fewer data available on these substances. Aims : The purpose of this study was to determine the prevalence of novel psychedelic use and the associations of novel psychedelic use with mental health outcomes. Methods : We estimated the prevalence of self-reported, [...]
Lire la suiteDisruptive Psychopharmacology Boris D. Heifets, MD, PhD1; Robert C. Malenka, MD, PhD2 JAMA Psychiatry. Published online June 26, 2019. doi:10.1001/jamapsychiatry.2019.1145 The paucity of medications with novel mechanisms for the treatment of mental illnesses combined with the delayed response to currently available medications has led to great excitement about the potential therapeutic utility of previously demonized drugs, which offer the hope of generating rapid symptom reductions in some of the sickest patients. Within the past 2 years, the US Food and Drug Administration approved esketamine for treatment-resistant depression and 2 compounds that are still on the US Drug Enforcement Administration’s most restrictive schedule, 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, [...]
Lire la suiteCANNABIS PEER REVIEW 1964-2016 Over 650 Peer Reviewed Reports & Studies On Cannabis A Free Jeff Prager Publication Health benefits, cancer fighting qualities and many other medicinal advantages can be attributed to the Cannabis Plant. Likewise, diseases and disorders are also related to smoking, vaping and ingesting components of the Cannabis Plant. Cannabis users should be aware and well informed regarding both the positive effects and the negative consequences of regular Cannabis use and this eBook accomplishes that goal by employing over 400 current peer reviewed reports and studies—their findings— with active hyper links to each report. A Free Jeff Prager No-Copyright Publication for [...]
Lire la suiteBrain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans : Evidence from Studies of Adult Users. Aviv Weinstein, Abigail Livny, Abraham Weizman. Current Pharmaceutical Design, 2016, 22, 42, 6366-6379. doi: 10.2174/1381612822666160822151323. PMID : 27549374 Abstract Cannabis is the most widely used illicit drug worldwide. Regular cannabis use has been associated with a range of acute and chronic mental health problems, such as anxiety, depression, psychotic symptoms and neurocognitive impairments and their neural mechanisms need to be examined. This review summarizes and critically evaluates brain-imaging studies of cannabis in recreational and regular cannabis users between January 2000 and January 2016. The [...]
Lire la suiteAwareness of Emotional Expressions in Cannabis Users : An Event-Related Potential Study Robert D. Torrence, Donald C. Rojas and Lucy J. Troup Frontiers in Psychology, February 2019 | Volume 10 | Article 69 ORIGINAL RESEARCH doi: 10.3389/fpsyg.2019.00069 Abstract Cannabis use has been associated with anxiogenic effects when used in low frequency for a short duration, but cannabis can also have anxiogenic effects when used heavily for a long duration. Animal studies have indicated the neurobiological mechanisms related to cannabis and anxiety; however, research has been limited on the related neurocognitive mechanisms. Previous research has indicated that cannabis use is associated with alterations in event-related potentials (ERPs). [...]
Lire la suiteCannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience Sagnik Bhattacharyya, Irina Falkenberg, Rocio Martin-Santos, Zerrin Atakan1, Jose A Crippa, Vincent Giampietro, Mick Brammer and Philip McGuire Neuropsychopharmacology, 2015, 40, 1343–1352 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org doi:10.1038/npp.2014.258 Abstract There is now considerable evidence to support the hypothesis that psychotic symptoms are the result of abnormal salience attribution, and that the attribution of salience is largely mediated through the prefrontal cortex, the striatum, and the hippocampus. Although these areas show differential activation under the influence of delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD), the two major derivatives of cannabis sativa, little is known about [...]
Lire la suite